Based on decades of experience with in vivo disease modeling, we can offer our clients a suite of tissue injury models reporting the ability of new drugs to suppress the inflammatory and fibrogenic processes in the liver or kidney.
Models we offer include:
- Bile duct ligation (BDL) induced cholestatic liver injury;
- Methionine Choline Deficient (MCD) dietary model of steatotic liver damage;
- Unilateral Utereral Obstruction (UUO) model of renal interstitial fibrosis.
According to the specific needs of our clients, we will carefully design bespoke prophylactic or therapeutic protocols that can report the efficacy of drugs for preventing, halting or reversing fibrosis in the context of ongoing tissue damage.